Hematocrit

The hematocrit test measures the proportion of erythrocytes in the blood to the total blood volume, providing direct information about oxygen-carrying capacity. Low or high values offer important clinical clues in the evaluation of anemia, dehydration, or hematologic disorders.

Analysis of hematocrit level plays a decisive role in distinguishing types of anemia. Changes in erythrocyte volume facilitate the detection of conditions related to iron deficiency, anemia of chronic disease, or vitamin deficiencies and contribute to shaping the treatment approach.

Serial hematocrit measurements are used in the assessment of fluid balance disorders. High hematocrit values are usually associated with dehydration, whereas low values may indicate conditions such as fluid overload or blood loss and directly affect clinical management.

Monitoring hematocrit is important for understanding the course of cardiovascular and hematologic diseases. Regular evaluation of the values allows early detection of polycythemia, chronic hypoxia, or bone marrow disorders and supports the planning of long-term treatment strategies.

What Is Hematocrit?

Hematocrit is a laboratory value that shows the proportion of red blood cells (erythrocytes) in the blood to the total blood volume. It is usually expressed as a percentage (%). A low hematocrit level may indicate anemia, while high levels may point to fluid loss or certain diseases. The hematocrit value is used in the assessment of general health status and the oxygen-carrying capacity of the blood.

What is the ideal hematocrit range for IVF treatment?

In general, for a woman of reproductive age, the “normal” hematocrit range may vary slightly between laboratories but is generally accepted to be between 36% and 48%.

However, in IVF treatment we do not look only at this “normal” range. This is not a “pass” or “fail” test. What is important is to interpret what this value means within your personal health status. For example, a hematocrit value of 37% and a value of 47% may both appear “normal” on paper. However, these two values can provide us with completely different clues in terms of treatment planning and risk management. The goal is to understand why this value is at that level and to foresee its possible effects on pregnancy success.

What can change the hematocrit value?

Your hematocrit value is dynamic and can show small fluctuations even within a single day. In a sensitive process such as IVF treatment, being aware of the factors that can affect this value allows us to interpret the results correctly.

The main conditions that can affect your hematocrit level are:

• Dehydration (the body being deprived of fluids)
• The altitude of the place where you live
• Pregnancy status
• Smoking
• Certain chronic lung or heart diseases

Two of these factors are particularly important during the IVF process. The first is dehydration, that is, the body being deprived of sufficient fluids. When you do not take in enough fluids, the “watery” part of your blood, called plasma, decreases. This causes the proportion of red blood cells to be artificially increased, leading hematocrit to show a “false” elevation. This does not mean that your blood has increased in amount; it only means it has become more concentrated.

The second factor is pregnancy. When a pregnancy begins, the body enters a remarkable adaptation process to support the baby, and the total blood volume (especially the plasma portion) increases significantly. Because the production of red blood cells cannot keep up with this pace, the blood becomes “diluted” and the hematocrit value naturally decreases. This is called “physiologic anemia of pregnancy” and is an expected, healthy condition.

How do low hematocrit levels affect fertility?

Low hematocrit medically means “anemia”, commonly known as “lack of blood”. The most common cause of anemia in women of reproductive age is “iron deficiency”.

Many people associate iron deficiency only with general symptoms such as fatigue, tiredness, hair loss, or brittle nails. However, iron is a mineral of vital importance for reproductive health.

Iron is not only the building block of hemoglobin, which gives blood its red color and carries oxygen. It also plays a “key” role in hundreds of critical biochemical reactions such as the healthy functioning of the ovaries and the uterus, the production of energy in cells, and DNA synthesis.

Iron deficiency and anemia can impair fertility through two main mechanisms:

Disruption of Hormonal Signals: The delicate hormonal signals from the brain (hypothalamus and pituitary) to the ovaries that give the command “ovulate” (especially the hormone LH) are directly affected by iron deficiency. When there is not enough iron in the body, the regulation of these signals may be disrupted. This can lead to delayed ovulation, menstrual irregularities, or in the worst-case scenario, complete cessation of ovulation (anovulation).

Cellular Oxygen Deficiency (Hypoxia): Low hematocrit means there are fewer red blood cells in the blood. This means less oxygen is carried to the tissues. The ovaries and the uterine lining (endometrium) are metabolically highly active tissues that consume a large amount of energy and oxygen. When they do not receive enough oxygen, they almost become “out of breath”. In an ovary that does not receive adequate oxygen, egg development and maturation are impaired, which directly reduces egg quality. Similarly, a uterine wall that is not sufficiently oxygenated becomes unsuitable for embryo implantation.

What are the risks of starting IVF treatment with low hematocrit?

Starting an IVF treatment with anemia or iron deficiency is like an exhausted runner starting a marathon. The likelihood of encountering serious difficulties at nearly every stage of the treatment increases.

The main problems caused by iron deficiency and low hematocrit during the IVF process are:

• Ovulatory dysfunction
• Fewer eggs being collected despite treatment
• A marked decrease in egg quality
• Reduced fertilization rates
• Lower rates of developing “excellent quality” embryos
• Reduced capacity of the uterine lining (endometrium) to accept the embryo
• Embryo implantation failure
• Increased early pregnancy losses (miscarriages)

To elaborate on this list a bit further, a scientific study demonstrated this effect in a striking way. The IVF outcomes of women with very low iron stores (ferritin) were compared with those of women whose iron stores were normal. The results were clear: the number of eggs fertilized in the laboratory was much lower in the group with iron deficiency.

However, the most critical finding was related to embryo quality. In women with iron deficiency, only about 23% of the embryos obtained were classified as “excellent quality”, whereas this rate was above 62% in the group with normal iron stores. This shows that iron deficiency directly sabotages the “developmental potential” and “energy” of the egg. In other words, without adequate iron, the chance of obtaining a healthy embryo is significantly reduced.

If pregnancy occurs after treatment, does low hematocrit harm the baby?

This is one of the most important issues that should be emphasized. The negative effects of anemia do not end when IVF treatment is successful and pregnancy is achieved; on the contrary, they may become even more critical.

Pregnancy is a period in which the body’s need for iron peaks. The body needs an enormous amount of iron to support the increased blood volume of the mother and for the development of the baby and placenta (the baby’s “afterbirth”). Especially in the last three months of pregnancy, the daily iron requirement nearly increases tenfold.

If a woman starts pregnancy with her “iron stores empty” or already anemic (low hematocrit), it becomes almost impossible for her to meet this increased demand.

Starting pregnancy with anemia or failing to treat anemia during pregnancy carries serious risks for both the mother and the baby.

Possible risks for the expectant mother are:

• Threat of preterm birth
• Premature rupture of membranes (water breaking early)
• Increased risk of preeclampsia (pregnancy toxemia)
• Excessive bleeding during and after delivery
• Possible risks for the baby are:
• Low birth weight
• Intrauterine growth restriction
• Hypoxia during birth
• Iron deficiency anemia in infancy

Moreover, research now shows that iron deficiency in the womb may have long-term effects on the baby’s later life. Iron is critically important for the baby’s brain development. There is strong evidence that severe iron deficiency during pregnancy can lead to adverse, and sometimes even irreversible, effects on the child’s later cognitive functions and behavioral development.

Therefore, detecting and “fully” correcting low hematocrit and iron deficiency before starting IVF treatment not only increases the chances of pregnancy, but also becomes one of the most important steps taken for a healthy next generation.

What does it mean if the hematocrit value is high?

Although not as common as low hematocrit, high hematocrit values are also a condition that must be handled with care in terms of IVF treatment.

When a patient’s blood test shows high hematocrit, the first thing that comes to mind is dehydration. Especially if sufficient water has not been consumed before the test, the blood becomes more concentrated and hematocrit may appear temporarily high. This is a simple situation that can be corrected by drinking plenty of water.

However, beyond this temporary situation, chronically high hematocrit may have serious medical causes referred to as “polycythemia”. Among these, the most concerning condition during the IVF process is a disease called Polycythemia Vera (PV).

Polycythemia Vera is a rare type of blood disease. In this condition, the bone marrow produces an excessive amount of red blood cells (and sometimes platelets, the clotting cells) in an almost “uncontrolled” manner. This causes the blood to become extremely viscous and “thick”. Although it is generally known as a disease of older age, it can also be seen in women of reproductive age and must be investigated in patients planning IVF treatment.

Why is high hematocrit dangerous in IVF treatment?

The main and life-threatening danger created by high hematocrit, especially when caused by underlying Polycythemia Vera, is the risk of CLOTTING (thrombosis).

Think of the blood as a normally free-flowing fluid. In Polycythemia Vera, however, the blood becomes thicker, almost like syrup or molasses. This thick and slow-flowing blood is extremely prone to forming clots within the vessels. These clots can pose life-threatening risks in the legs (deep vein thrombosis), lungs (pulmonary embolism), or brain (stroke).

Now let us combine this situation with IVF treatment:

• Baseline Risk: The patient already has a high tendency to clot due to Polycythemia Vera.
• Treatment Risk: The hormones used to stimulate the ovaries in IVF treatment, especially the rising estrogen levels, “naturally” increase the tendency of the blood to clot to some extent.
• Pregnancy Risk: Pregnancy itself is a process that activates the coagulation system as a precaution the body takes to prevent bleeding during delivery.

For this reason, an IVF treatment and subsequent pregnancy in a woman with Polycythemia Vera create an extremely high risk of thrombosis that can be described as a “triple hit”. This is a condition that requires the highest level of attention and management for the life of the expectant mother and the health of the pregnancy.

Is pregnancy possible if high hematocrit (polycythemia) is brought under control?

Yes, it is possible for women with a diagnosis of Polycythemia Vera to become pregnant. However, this is a “high-risk pregnancy” process that must be managed in close collaboration between a hematology (blood diseases) specialist and an IVF specialist.

The main adverse effect of high hematocrit and thick blood on pregnancy occurs through the placenta. The placenta is an organ composed of millions of fine capillaries that provides the exchange of nutrients and oxygen between the mother and the baby.

Excessively viscous and clot-prone blood may block these delicate capillaries in the placenta (microthrombosis). This can impair blood flow to the baby and lead to placental insufficiency.

If this condition and high hematocrit are not brought under control before starting treatment, the following serious problems may occur during pregnancy:

• Recurrent pregnancy losses (especially in the first trimester)
• Intrauterine growth restriction
• Preeclampsia (pregnancy toxemia)
• Placental abruption
• Sudden intrauterine fetal death

However, this picture does not have to be pessimistic. With appropriate treatment and close monitoring, these risks can be significantly reduced. Scientific data are very clear on this point: In women with Polycythemia Vera who receive treatment (aspirin, anticoagulant injections, procedures to lower hematocrit), the rate of having a live and healthy baby exceeds 78%, whereas in the group that is untreated or inadequately treated, this rate remains much lower.

Why is hematocrit so important in the dangerous complication called ‘OHSS’?

Perhaps the most critical and dynamic role of hematocrit in IVF treatment appears in the monitoring of a serious complication called OHSS (Ovarian Hyperstimulation Syndrome).

OHSS occurs when the ovaries respond excessively to ovarian stimulation treatment (especially to the hormone hCG, known as the trigger shot). In this situation, the enlarged ovaries secrete certain chemical substances (especially VEGF) into the blood.

These substances disrupt the “tightness” of blood vessels throughout the body. The vessels start to act almost like a “sieve”. The “watery” part of the blood, called plasma, leaks out of the vessels and begins to accumulate in the abdominal cavity (ascites) and sometimes between the membranes of the lungs (hydrothorax).

This has two main consequences: fluid accumulation in the abdominal cavity (bloating, pain, shortness of breath) and, even more dangerously, a decrease in intravascular volume (hypovolemia).

This is where hematocrit comes into play. As the “watery” part of the blood (plasma) leaks out, the proportion of red blood cells remaining in the vessels increases. The blood becomes “thicker” or more “concentrated”. This is called “hemoconcentration”.

The hematocrit value is the simplest, cheapest, and most effective laboratory test that directly measures this dangerous thickening. If a patient’s hematocrit value begins to rise in serial measurements, this is the most important “alarm bell” indicating that the body is losing dangerous amounts of fluid and that OHSS is becoming more severe.

How do doctors use hematocrit values to assess the severity of OHSS?

The hematocrit value is one of the most objective laboratory criteria used to classify the severity of OHSS. The patient’s sense of bloating or nausea is important, but hematocrit gives us clear numbers about how critical the intravascular situation is.

Clinically, we use hematocrit threshold values as a guide when classifying OHSS. A general classification is as follows:

• Mild OHSS: Hematocrit is usually below 41%.
• Moderate OHSS: Hematocrit begins to rise into the 41–45% range.
• Severe OHSS: Hematocrit rises above 45%.
• Critical OHSS: Hematocrit rises above 55%.

As you can see, the difference between a hematocrit of 44% and 46% can mean the difference between outpatient follow-up and hospitalization. A value above 55% indicates a critical condition in which the risk of thromboembolism, renal failure, or respiratory failure is very high and urgent intensive care intervention is required.

How does the hematocrit value influence the embryo transfer decision?

The most strategic use of hematocrit in IVF treatment occurs when making the decision on “fresh embryo transfer”.

There are two types of OHSS: “early” (starts immediately after egg retrieval) and “late” (triggered by the onset of pregnancy). Late OHSS tends to be much more severe and prolonged because it is triggered by rising levels of the pregnancy hormone hCG in the blood. The most important task of IVF specialists is to protect the patient from this dangerous “late OHSS” scenario.

For this purpose, we measure hematocrit at strategic times. In particular, a hematocrit value is checked on the day of egg retrieval (OPU). The truly critical moment is the day when embryo transfer is planned (3 or 5 days after egg retrieval).

If the hematocrit value in the blood test performed on the day of embryo transfer has risen above a predetermined threshold (for example 35%) OR shows a significant increase (for example 3% or more) compared with the baseline value on the day of egg retrieval, this is a sign that the body has already entered the OHSS process and started to leak fluid out of the vessels.

In this situation, performing a “fresh transfer”, that is, placing the embryo into the uterus in that same cycle, would be like pouring fuel on the fire. If that embryo implants and pregnancy begins, the rising hCG hormone can drive the OHSS picture to critical levels.

When we see this risky signal (rising hematocrit), we put the patient’s safety first and make the best decision: freezing all healthy embryos (“freeze-all”). With this strategy, no fresh transfer is performed in that cycle. We wait for the body to recover, the hormones to return to normal, the vascular permeability to improve, and the hematocrit to return to normal levels. About 1–2 months later, when the patient is completely healthy and safe, the frozen high-quality embryo is transferred into a much safer uterine environment.

Can a hematocrit value within the normal range predict IVF success?

This is a rather interesting question that has attracted the attention of the scientific community in recent years. Generally, the focus is on “abnormal” values such as anemia (low hematocrit) or polycythemia (high hematocrit. But what if everything is within the “normal” range?

Some recent scientific studies have suggested that hematocrit values close to the “upper limits” of the normal range may modestly affect IVF success. In one study, it was found that as the pre-treatment hematocrit value increased, the rate of achieving clinical pregnancy decreased statistically.

The theory behind this is related to blood viscosity. As hematocrit increases, blood viscosity increases (the blood becomes more “sticky”). The uterine lining (endometrium), where the embryo will implant, is supplied by a network of extremely fine capillaries. Reduced blood fluidity may impair blood flow (microcirculation) in these terminal capillaries. This may hinder the adequate nourishment and oxygenation of the “bed” in which the embryo will implant, making implantation more difficult.

However, this finding is not yet accepted as “definitive” and remains a topic of debate in the scientific community. On the contrary, other scientific studies have not found such a clear relationship between hematocrit values and IVF success. IVF success is strongly influenced by much more powerful factors such as female age, egg quality, sperm quality, and embryo genetics. Compared to these major factors, the effect of fluctuations in hematocrit within the “normal range” may be statistically too small to be seen.

What should be done when low hematocrit and iron deficiency are detected?

One of the most critical and highest-yield steps in treatment planning is treating anemia and iron deficiency “at the right time and in the right way”.

The ideal protocol to follow includes the following steps:

Comprehensive Screening: In every woman considering treatment, not only a complete blood count (to see hematocrit and hemoglobin) but also the “serum ferritin” level should be measured. Ferritin shows the body’s “iron stores”. Sometimes anemia (low hematocrit) may not yet have developed, but your iron stores (ferritin) may already be completely depleted. Detecting this “hidden” deficiency is very important.

Choosing an Effective Treatment Method: Once deficiency is detected, the stores must be replenished. Depending on the severity of the deficiency, the patient’s condition, and the treatment timeline, two main methods can be chosen:

• Oral iron medications (tablets)
• Intravenous (IV) iron therapy

Intravenous iron therapy is especially useful when the stores are very low or when there are problems with oral medications; it rapidly replenishes the stores in 1–2 sessions, saving us time.

Critical Timing (The Most Important Step): This is the most important point that directly affects the success of treatment. Scientific studies have shown that starting IVF treatment in the same month immediately after beginning iron supplementation does not “correct” the negative effects on egg and embryo quality. This is because it takes “time” for the follicular fluid in which the egg develops to become rich in iron and for the egg to mature in this healthy environment.

The ideal and scientifically proven protocol is as follows: First, iron deficiency is treated and the replenishment of stores is confirmed by blood tests. Then, about two months are allowed for the eggs to develop and mature in this new, healthy, iron-rich environment. Only after this waiting period is the IVF treatment (ovarian stimulation) started. This strategy maximizes embryo quality.

How is the treatment process planned in the case of high hematocrit (polycythemia)?

Starting IVF treatment “immediately” in a patient with high hematocrit (polycythemia) and especially in whom a disease such as Polycythemia Vera (PV) is suspected is extremely dangerous. Here, a “team effort” is essential. The IVF specialist must manage the process together with a hematology (blood diseases) specialist.

The safe roadmap to follow includes the following steps:

• Mandatory hematology consultation before treatment
• Clarifying the cause of high hematocrit (PV diagnosis)
• Stopping drugs that may be harmful in pregnancy (e.g., hydroxyurea) at least 3 months in advance
• Switching to medications that are safe in pregnancy when necessary (e.g., interferon-alpha)
• Lowering the hematocrit level to a safe range (below 45%)
• Planning phlebotomy procedures (venesection) to dilute the blood when necessary
• Starting low-dose aspirin to reduce the risk of thrombosis
• Using anticoagulant injections (LMWH) during treatment and pregnancy when necessary

Only after all these risks are brought under control, the hematocrit is lowered to a safe level, and the hematology specialist gives approval that “pregnancy is safe”, can IVF treatment be initiated with confidence.

Frequently Asked Questions